Genmab is a biotechnology company specializing in the creation and development of differentiated human antibody therapeutics focused on the treatment of cancer. Co.'s product pipeline includes one marketed product, Arzerra, daratumumab in late stage clinical development, four antibodies in clinical development, and over 20 in-house and partnered pre-clinical programs. Co.'s Arzerra (ofatumumab) is a human monoclonal antibody which targets an epitope on the CD20 molecule. Co.'s proprietary technologies include the DuoBody technology, which creates antibodies that can target two molecules at once, and the HexaBody technology, which allows for the creation of more potent antibodies.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Capital Increase in Genmab as a Result of Employee Warrant Exercise Company Announcement COPENHAGEN, Denmark; September 27, 2022 – (Nasdaq: GMAB) will increase its share capital by 18,406 shares as a consequence of the exercise of employee warrants. The increase is effected without any preemption rights for the existing shareholders of the company or others. The shares are subscribed in cash at the following price per share of nominally DKK 1: 133 shares at DKK 815.50,3,874 shares at DKK 939.50,367 shares at DKK 962.00,8,949 shares at DKK 1,025.00,878 shares at DKK 1,032.00,50 shares at...
Grant of Restricted Stock Units and Warrants to Employees in Genmab Company Announcement COPENHAGEN, Denmark; September 20, 2022 – (Nasdaq: GMAB) announced today that the board decided to grant 19,782 restricted stock units and 19,789 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a right and obligation to receive one share in Genmab A/S of nominally DKK 1. The fair value of each restricted stock unit is equal to the closing market price on the date of grant of one Genmab A/S share, DKK 2,5...
Genmab to Present at Morgan Stanley 20th Annual Global Healthcare Conference Media ReleaseCOPENHAGEN, Denmark; September 6, 2022 (Nasdaq: GMAB) announced today that its Chief Executive Officer Jan van de Winkel, Ph.D. and Chief Financial Officer Anthony Pagano will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference at 8:00 AM EDT / 2:00 PM CEST on September 13, 2022. A webcast of the event, which will include brief opening remarks followed by a question-and-answer session, will be available on Genmab’s website at About Genmab Genmab is an inter...
Yesterday Iliad broke the suspense and announced the roll-out of its proprietary payment service named Stancer. Despite a hyped-up launch, we see very limited implications for our payments coverage from a competitive standpoint. º Solid progress across the board Opex assumptions remain unchanged We reiterate our Target Price of EUR83
Nexi held its Capital Markets Day (CMD) yesterday, laying out a strategic plan whose execution is expected to deliver a 9% organic sales CAGR and a 900bp progression in EBITDA margin by 2025e. These figures are bang in line with sell-side expectations. However, the growth and profitability path described at the CMD is far from reflected in the stock price, thus reinforcing our conviction on the stock’s potential.
Unfortunately, this report is not available for the investor type or country you selected.Browse all ResearchPool reports
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.